CoVLP

Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine

Retrieved on: 
Thursday, February 24, 2022

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).

Key Points: 
  • Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted).
  • The approval of our COVID-19 vaccine is a significant milestone for Canada in the fight against the pandemic.
  • We look forward to working with Medicago to make the vaccine available in Canada and to progress further regulatory submissions.
  • The Government of Canada has a contract with Medicago (the Marketing Authorization Holder) to supply the COVID-19 vaccine.

Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate

Retrieved on: 
Tuesday, June 8, 2021

We are pleased to be working with Seqirus to evaluate MF59 in combination with IVX-411, our COVID-19 VLP vaccine candidate.

Key Points: 
  • We are pleased to be working with Seqirus to evaluate MF59 in combination with IVX-411, our COVID-19 VLP vaccine candidate.
  • The Phase 1/2 clinical trial is a randomized, observer-blinded, placebo-controlled trial designed to evaluate the safety and immunogenicity of adjuvanted and unadjuvanted IVX-411.
  • The Phase 2 part of the trial will enroll SARS-CoV-2 seropositive adults who have completed a vaccine regimen using a licensed COVID-19 vaccine.
  • Icosavax is advancing VLP vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2 (COVID-19).

Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate

Retrieved on: 
Tuesday, March 16, 2021

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicagos plant-derived COVID-19 vaccine candidate in combination with GSKs pandemic adjuvant, as part of the ongoing Phase 2/3 study.

Key Points: 
  • Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicagos plant-derived COVID-19 vaccine candidate in combination with GSKs pandemic adjuvant, as part of the ongoing Phase 2/3 study.
  • Medicago received approval from Canadian and US regulatory authorities to proceed with enrollment of healthy adults in the Phase 3 portion of the trial based on positive interim Phase 2 results.
  • In parallel, Medicago has also initiated a feasibility study of a vaccine candidate to address the emerging COVID-19 variants.
  • We are pleased to take the significant step of initiating the Phase 3 clinical trial at sites around the world, said Takashi Nagao, CEO and President of Medicago.